Objectives:The importance of TRAILdeathreceptor expression inpancreatic carcinoma development is not known. To reveal the putative connection ofDR4and DR5receptor expression profile to thisprocess, we analyzed and compared the expression profile of TRAILdeath receptors in pancreatic tissues of patients with pancreaticcancer (PC).　　Methods:Twenty-eight PC patients wereincluded in the study. TRAILdeath receptor expression profiles were determined by immunohistochemistry.　　Result:1, the expression of DR4, DR5 next to pancreatic cancer and non-cancer cell carcinoma　　Beside all pancreatic cancer cells and non-cancer tissues were visible expression ofDR4 and DR5. And pancreatic tissue expression of DR4 and DR5 were significantly higher than the adjacent tissues (P <0.05), the difference was statistically significant. In bothorganizations, the expression of DR4 was significantly stronger than DR5 (P <0.05), the difference was statistically significant.2, DR4, expression and differentiation of pancreatic cancer staging and DR5 relationship DR4, DR5 expression and the clinical staging. The resultsshows stageI tumors DR4, DR5 expression was significantly higher than thestageII, III, IV tumors (P <0.05).In contrast,expression of DR4, DR5was decreased with decreased in degree of differentiation in tumors,but the difference was not statistically significant.　　Conclusion:Because PC is resistant to conventional treatmentmethods and exhibits high mortality rates, novel treatmentmodalities are needed to improve survival rates of PCpatients. Furthermore, there is also a necessity to discover newPC tumor markers for both diagnostic and prognostic purposes.Differential alterationofTRAIL receptorexpression profiles in PCpatients suggest that theTRAILreceptorDR4 and DR5 may play a pivotal role during pancreatic carcinomadevelopment.